Technical Report Physical Medicine & Rehabilitation Public Health Quality Improvement
30-day readmission after pharmacist-led medication review in critically ill adults: A case series

30-day readmission after pharmacist-led medication review in critically ill adults: A case series

Authors

Malik Kaur

Malik Kaur

American University of Beirut Medical Center, Kyrgyzstan

Malik Larsen

Malik Larsen

Karolinska University Hospital, Venezuela

Amira Kaur

Amira Kaur

Royal Melbourne Hospital, Thailand

Ethan Ahmed

Ethan Ahmed

Royal Melbourne Hospital, Slovakia

Corresponding

Published

August 28, 2024

Paper ID

PAP-000253

Status

Published

DOI

10.65712/tmj.test000511

30-day readmission after pharmacist-led medication review in critically ill adults: A case series

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around pharmacist-led medication review varies widely between centres. Methods: Missing data were handled with multiple imputation. Results: 1753 participants were included (median age 62 years). The adjusted odds ratio was 0.52 (95% CI 0.35 to 0.72). Conclusion: Residual confounding cannot be excluded.

Introduction

Earlier studies of pharmacist-led medication review were small or single-centre. 30-day readmission remains a leading cause of avoidable harm among critically ill adults.

Practice around pharmacist-led medication review varies widely between centres. 30-day readmission remains a leading cause of avoidable harm among critically ill adults. The cost of 30-day readmission to health systems is substantial. Earlier studies of pharmacist-led medication review were small or single-centre.

Discussion

Implementation will depend on staffing, cost and local protocols. These findings suggest that pharmacist-led medication review is associated with better 30-day readmission in critically ill adults.

These findings suggest that pharmacist-led medication review is associated with better 30-day readmission in critically ill adults. Implementation will depend on staffing, cost and local protocols.

Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.

Implementation will depend on staffing, cost and local protocols. These findings suggest that pharmacist-led medication review is associated with better 30-day readmission in critically ill adults. Future work should test pharmacist-led medication review in a pragmatic multicentre trial.

Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.

Conclusions

Pharmacist-led medication review is a reasonable option for critically ill adults to improve 30-day readmission.

References

1. Novak E, Andersen V, et al. Point-of-care ultrasound and 30-day readmission. BMJ. 2011;184(6):757-1237.

2. Haddad L, Mensah F, et al. Prone positioning and in-hospital mortality. BMJ. 2024;122(5):877-1467.

3. Schmidt G, Mueller V, et al. Home-based cardiac rehabilitation and post-operative delirium. Eur Heart J. 2022;151(1):623-1738.

4. Rahman W, Schmidt J, et al. Home-based cardiac rehabilitation and length of stay. Lancet. 2014;108(6):469-1715.

5. Lindqvist I, Costa G, et al. Prone positioning and ventilator-free days. BMJ. 2017;391(11):62-1112.

6. Andersen Y, Ibrahim X, et al. Nurse-led discharge planning and ventilator-free days. JAMA. 2022;252(10):234-916.

Appendices

Supplementary tables are available on request.

Materials and Methods

Eligible participants were critically ill adults. The primary outcome was 30-day readmission, assessed blind to allocation.

The primary outcome was 30-day readmission, assessed blind to allocation. We conducted a case series across 13 centres between 2018 and 2023.

Eligible participants were critically ill adults. We conducted a case series across 12 centres between 2020 and 2023.

Analyses were adjusted for age, sex and baseline severity. The primary outcome was 30-day readmission, assessed blind to allocation. We conducted a case series across 12 centres between 2015 and 2023.

Results

4054 participants were included (median age 34 years). 2810 participants were included (median age 61 years).

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.57 (95% CI 0.42 to 0.70).

30-day readmission occurred in 14% of the intervention group versus 36% of controls. 30-day readmission occurred in 13% of the intervention group versus 29% of controls. 585 participants were included (median age 55 years). 1424 participants were included (median age 80 years).

GroupnEventsRate %OR95% CI
Age < 6581410224.80.880.45–1.16
Male5742631.80.800.44–1.3
Female45929.90.650.26–1.30
Female786599.40.930.49–1.15
Centre A6533122.10.910.60–1.35
Control56209.30.700.47–1.39
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in 30-day readmission
Shown for critically ill adults; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Kaplan–Meier curve for 30-day readmission
Shown for critically ill adults; error bars are 95% confidence intervals.

The adjusted odds ratio was 0.81 (95% CI 0.26 to 0.90). The adjusted odds ratio was 0.84 (95% CI 0.26 to 0.99).

30-day readmission occurred in 18% of the intervention group versus 25% of controls. Effects were consistent across prespecified subgroups. 30-day readmission occurred in 17% of the intervention group versus 14% of controls. Serious adverse events were rare and similar between groups.